Sign in Get Started

Loading company

Every figure taken straight from a company’s own SEC filings, with the checks behind each grade shown — and whatever could not be found named rather than hidden.

Appearance

Product

Screener
Earnings calendar
Watchlists
Portfolios

Browse

Industries
Themed lists
Fund managers

Company

About
Pricing
Contact

Legal

Terms of service
Privacy policy
Disclaimer
Cookie policy

© 2026 InspectStocks. All rights reserved.

InspectStocks describes businesses using their own reported figures. It is not investment advice and does not recommend buying or selling anything.

Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Vertex Pharmaceuticals Inc. / MA (VRTX) stock — is it a good business? — InspectStocks

Vertex Pharmaceuticals Inc. / MA

VRTX · Nasdaq · Healthcare · Biotechnology

Next earnings: November 2, 2026

$526.19+0.7%Sep 25 close

1M: -2.9%
6M: +21.5%
1Y: +36.4%
5Y: +184.3%

Vertex develops and sells medicines for cystic fibrosis, inherited blood disorders, acute pain, and other serious diseases.

VRTXVertex Pharmaceuticals Inc. / MA$526.19Sep 25 close+0.7%1M-2.9%6M+21.5%1Y+36.4%5Y+184.3%

Overview Financials Earnings Peers Projection Compare

Built from Vertex Pharmaceuticals Inc. / MA’s own filings with the SEC. Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.

Full financial statements →

About Vertex Pharmaceuticals Inc. / MA

Vertex discovers, tests, manufactures, and sells prescription medicines. Its approved medicines treat cystic fibrosis, severe sickle cell disease, transfusion-dependent beta thalassemia, and moderate-to-severe acute pain; it is also testing treatments for kidney disease, type 1 diabetes, and other conditions. It sells mainly through specialty pharmacies, distributors, and wholesalers, with some gene therapy supplied directly to treatment centers.

Head office: Boston, Massachusetts
Founded: 1989
Employees: 6,400 (December 31, 2025, high)
Listed on: NASDAQ
Financial year ends: December 31

How it makes money

TRIKAFTA/KAFTRIO sales75%
ALYFTREK sales17%
KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI sales4%
CASGEVY sales2%
JOURNAVX sales2%

Shares of revenue are estimates for quarter ended June 30, 2026, not figures from a filing.

Competes with

What it sells5

ALYFTREK
A once-daily combination medicine that improves the function of the faulty protein that causes cystic fibrosis.
TRIKAFTA/KAFTRIO
A combination medicine that improves the function of the faulty protein that causes cystic fibrosis. TRIKAFTA and KAFTRIO are brand names used in different markets.
KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI
Other medicines for cystic fibrosis that improve the function of the protein involved in the disease.

Show 2 more

CASGEVY
A gene-editing treatment for severe sickle cell disease and transfusion-dependent beta thalassemia. A patient's blood-forming cells are collected, edited at a manufacturing facility, and returned for infusion.
JOURNAVX
An oral, non-opioid medicine for moderate-to-severe acute pain in adults.

Who buys it5

Specialty pharmacies and specialist distributors buy Vertex medicines and resell them to patients, pharmacies, health care providers, hospitals, or treatment centers.
Major wholesalers in the United States buy Vertex medicines for resale through pharmacies and health care providers.
Outside the United States, distributors, retail pharmacies, hospitals, and clinics buy or distribute medicines; some hospitals and clinics are government-owned or supported.

Show 2 more

Authorized treatment centers can receive CASGEVY directly from Vertex in some markets.
Government health programs and commercial insurers decide whether to cover medicines and reimburse purchases.

What it stands on, and what could break it

What the business leans on

1The business depends substantially on cystic fibrosis medicines; sales therefore depend on continued patient use, access, and the medicines' ability to compete with other treatments.
2Vertex relies on outside manufacturers and suppliers for much of its commercial and clinical supply. CASGEVY also requires coordinated cell collection, editing, shipping, and treatment-center infusion.
3

How it compares with its industry

Three ratings, each a percentile against the 585 companies we cover in Biotechnology. Deliberately kept apart rather than blended into one score — cheap, rising and well-run are three different facts, and a single number would hide which one is which.

Momentum

64of 100 in its industry

Above most of its industry

12 months to a month ago42.1%

6 months to a month ago14.4%

The most recent month is left out on purpose: returns tend to persist over 7–12 months and the newest one tends to reverse. This describes what the price has done, and says nothing about what it will do.

Value

61of 100 in its industry

Above most of its industry

Profit for the price3.30%

Cash for the price2.85%

Sales for the price9.44%

Assets for the price14.00%

Operating profit for the whole business3.40%

Yields, so higher means cheaper — a loss-making company ranks last instead of dropping out. Cheap is not the same as good: a high yield is often a price that fell for a reason. All five measures available.

Capital allocation

5/5Disciplined

1 check not reported

Return on capital17.4%

Shareholder yield1.51%

Share count, 3 years-2.2%

Net debt / EBITDA-1.04x

Insiders, 12 months-$143.7M

What management does with the money — scored on whatever the filings answer, never as a share of the total.

The six capital-allocation checks

Return on the money invested17.4% on invested capital
Debt against earningsMore cash than debt
Cash returned to shareholders1.5% a year in buybacks and dividends
Share count over three yearsShare count 2.2% lower over three years
Payouts covered by cash flowFree cash flow covers what it pays out
Open-market insider buyingNet selling of $143.7M — not counted against the score

A description of where this company sits among its competitors, not a recommendation. Ratings updated Sep 26, 2026.

Sales depend on government programs and commercial insurers covering medicines and agreeing to reimbursement terms. The company also pays royalties on certain cystic fibrosis medicines and shares CASGEVY profits with CRISPR Therapeutics.

What could go wrong

1The company identifies its cystic fibrosis medicines as a substantial source of business dependence. Competing treatments, changes in patient use, or loss of patent protection could reduce sales.
2Vertex's future products depend on clinical trials showing acceptable safety and benefit and on regulators approving them. A delay or failure in programs such as povetacicept, inaxaplin, or zimislecel could limit its ability to add new medicines.
3The company relies on complex supply chains, outside manufacturers, and treatment-center coordination, particularly for cell and gene therapies. Manufacturing or distribution problems could delay or interrupt supply.

bluebird bio

TVTXTravere Therapeutics

Size: $5.6B
Margin: -7.4%

Size: $277.6B
Margin: -0.1%

PCRXPacira BioSciences

Size: $1B
Margin: 2.0%

B+

Is the business getting bigger, and does it generate real cash?

Grade in force:

ABCDF

Showing 2 of 41 quarters of Vertex Pharmaceuticals Inc. / MA’s grade history. The other 39 go back to September 2016.

See all of it with Pro →